Information de reference pour ce titreAccession Number: | 00130417-201406010-00009.
|
Author: | Schumacher-Schuh, Artur F 1,2; Rieder, Carlos RM 2,3; Hutz, Mara H *,1
|
Institution: | (1)Departamento de Genetica, Instituto de Biociencias, UFRGS, Caixa Postal 15053, 91501-970, Porto Alegre, RS, Brazil (2)Servico de Neurologia, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil (3)Universidade Federal de Ciencias da Saude de Porto Alegre, Porto Alegre, Brazil
|
Title: | Parkinson's disease pharmacogenomics: new findings and perspectives.[Review]
|
Source: | Pharmacogenomics. 15(9):1253-1271, June 2014.
|
Abstract: | : Parkinson's disease (PD) is unique among neurodegenerative disorders because a highly effective pharmacological symptomatic treatment is available. The marked variability in drug response and in adverse profiles associated with this treatment led to the search of genetic markers associated with these features. We present a review of the literature on PD pharmacogenetics to provide a critical discussion of the current findings, new approaches, limitations and recommendations for future research. Pharmacogenetics studies in this field have assessed several outcomes and genes, with special focus on dopaminergic genes, mainly DRD2, which is the most important receptor in nigrostriatal pathway. The heterogeneity in methodological strategies employed by different studies is impressive. The question of whether PD pharmacogenetics studies will improve clinical management by causing a shift from a trial-and-error approach to a pharmacological regimen that takes into account the individual variability remains an open question. Collaborative longitudinal studies with larger sample sizes, better outcome definitions and replication studies are required.
(C) 2014Future Medicine, Ltd.
|
Author Keywords: | adverse effects; dopamine receptors; dopaminergic agents pharmacogenetics; levodopa; Parkinson's disease.
|
References: | 1 Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2), 197-211 (2003).
2 De Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 5 (6), 525-535 (2006).
3 Fox SH, Lang AE. Levodopa-related motor complications-phenomenology. Mov. Disord. 23 (Suppl. 3), S509-S514 (2008).
4 Wang J, Liu ZL, Chen B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology 56 (12), 1757-1759 (2001).
5 Oliveri RL, Annesi G, Zappia M et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 53 (7), 1425-1430 (1999). * First study to investigate pharmacogenetics of levodopa-induced dyskinesia.
6 Zappia M, Annesi G, Nicoletti G et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch. Neurol. 62 (4), 601-605 (2005).
7 Strong JA, Dalvi A, Revilla FJ et al. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. Mov. Disord. 21 (5), 654-659 (2006).
8 Rieck M, Schumacher-Schuh AF, Altmann V et al. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. Pharmacogenomics 13 (15), 1701-1710 (2012).
9 Makoff AJ, Graham JM, Arranz MJ et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics 10 (1), 43-48 (2000).
10 Vallelunga A, Flaibani R, Formento-Dojot P, Biundo R, Facchini S, Antonini A. Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. Parkinsonism Relat. Disord. 18 (4), 397-399 (2012).
11 Rissling I, Geller F, Bandmann O et al. Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks." Mov. Disord. 19 (11), 1279-1284 (2004).
12 Paus S, Grunewald A, Klein C et al. The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease. Mov. Disord. 23 (4), 599-602 (2008).
13 Arbouw ME, Movig KL, Egberts TC et al. Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease. Eur. J. Clin. Pharmacol. 65 (12), 1245-1251 (2009).
14 Wang J, Liu ZL, Chen B. Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease. Neurosci. Lett. 308 (1), 21-24 (2001).
15 Liu Y-Z, Tang B-S, Yan X-X et al. Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients. Eur. J. Clin. Pharmacol. 65 (7), 679-683 (2009).
16 Lee J-Y, Cho J, Lee E-K, Park S-S, Jeon BS. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease. Mov. Disord. 26 (1), 73-79 (2011). * Shows the genetic differences between peak of dose dyskinesia and diphasic dyskinesia.
17 Paus S, Gadow F, Knapp M, Klein C, Klockgether T, Wullner U. Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism. Mov. Disord. 24 (7), 1080-1084 (2009).
18 Goetz CG, Burke PF, Leurgans S et al. Genetic variation analysis in Parkinson disease patients with and without hallucinations: case-control study. Arch. Neurol. 58 (2), 209-213 (2001).
19 Paus S, Seeger G, Brecht HM et al. Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease. Mov. Disord. 19 (6), 705-707 (2004).
20 Bialecka M, Drozdzik M, Klodowska-Duda G et al. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. Acta Neurol. Scand. 110 (4), 260-266 (2004).
21 Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Tan E-K, Drozdzik M. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet. Genomics 18 (9), 815-821 (2008).
22 Cheshire P, Bertram K, Ling H et al. Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease. Neurodegener. Dis. 13 (1), 24-28 (2014). * An important study with 285 pathologically confirmed Parkinson's disease patients using a longitudinal design.
23 Yin B, Chen Y, Zhang L. Association between catechol-O-methyltransferase (COMT) gene polymorphisms, Parkinson's disease, and levodopa efficacy. Mol. Diagn. Ther. doi:10.1007/s40291-013-0066-z (2013) (Epub ahead of print).
24 De Lau LM, Verbaan D, Marinus J, Heutink P, van Hilten JJ. Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease. Mov. Disord. 27 (1), 132-135 (2012).
25 Watanabe M, Harada S, Nakamura T et al. Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease. Neuropsychobiology 48 (4), 190-193 (2003).
26 Frauscher B, Hogl B, Maret S et al. Association of daytime sleepiness with COMT polymorphism in patients with Parkinson disease: a pilot study. Sleep 27 (4), 733-736 (2004).
27 Rissling I, Frauscher B, Kronenberg F et al. Daytime sleepiness and the COMT val158met polymorphism in patients with Parkinson disease. Sleep 29 (1), 108-111 (2006).
28 Camicioli R, Rajput A, Rajput M et al. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations. Mov. Disord. 20 (8), 989-994 (2005).
29 Chong DJ, Suchowersky O, Szumlanski C, Weinshilboum RM, Brant R, Campbell NR. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Clin. Neuropharmacol. 23 (3), 143-148 (2000).
30 Corvol J-C, Bonnet C, Charbonnier-Beaupel F et al. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. Ann. Neurol. 69 (1), 111-118 (2011). ** First clinical trial oriented by pharmacogenetic information.
31 Kaiser R, Hofer A, Grapengiesser A et al. L-dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 60 (11), 1750-1755 (2003).
32 Contin M, Martinelli P, Mochi M et al. Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease. Clin. Neuropharmacol. 27 (3), 111-115 (2004).
33 Schumacher-Schuh AF, Francisconi C, Altmann V et al. Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease. Int. J. Neuropsychopharmacol. doi: http://dx.doi.org/10.1017/S14611...- ouverture dans une nouvelle fenêtre (2013) (Epub ahead of print).
34 Kaplan N, Vituri A, Korczyn AD et al. Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease. J. Mol. Neurosci. 53 (2), 183-188 (2014).
35 Torkaman-Boutorabi A, Shahidi GA, Choopani S et al. The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease. Acta Neurobiol. Exp. (Warsz.) 72 (3), 272-282 (2012).
36 Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics 12 (1), 79-82 (2011).
37 Devos D, Lejeune S, Cormier-Dequaire F et al. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease. Parkinsonism Relat. Disord. 20 (2), 170-175 (2014).
38 Lee MS, Lyoo CH, Ulmanen I, Syvanen AC, Rinne JO. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. Neurosci. Lett. 298 (2), 131-134 (2001).
39 Contin M, Martinelli P, Mochi M, Riva R, Albani F, Baruzzi A. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease. Mov. Disord. 20 (6), 734-739 (2005).
40 Lee MS, Kim HS, Cho EK, Lim JH, Rinne JO. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. Neurology 58 (4), 564-567 (2002).
41 Kim JS, Kim J-Y, Kim J-M et al. No correlation between COMT genotype and entacapone benefits in Parkinson's disease. Neurol. Asia 16 (3), 211-216 (2011).
42 Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum. Mutat. 23 (6), 540-545 (2004).
43 Hoenicka J, Quinones-Lombrana A, Espana-Serrano L et al. The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine. Biol. Psychiatry 67 (1), 3-11 (2010).
44 Bontempi S, Fiorentini C, Busi C, Guerra N, Spano P, Missale C. Identification and characterization of two nuclear factor-kappaB sites in the regulatory region of the dopamine D2 receptor. Endocrinology 148 (5), 2563-2570 (2007).
45 Dearry A, Gingrich JA, Falardeau P, Fremeau RT Jr, Bates MD, Caron MG. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 347 (6288), 72-76 (1990).
46 Van de Giessen E, de Win MM, Tanck MW, van den Brink W, Baas F, Booij J. Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J. Nucl. Med. 50 (1), 45-52 (2009).
47 Volkow ND, Ding YS, Fowler JS et al. Dopamine transporters decrease with age. J. Nucl. Med. 37 (4), 554-559 (1996).
48 Bannon MJ, Whitty CJ. Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology 48 (4), 969-977 (1997).
49 Shumay E, Chen J, Fowler JS, Volkow ND. Genotype and ancestry modulate brain's DAT availability in healthy humans. PLoS ONE 6 (8), e22754 (2011).
50 Rubie C, Schmidt F, Knapp M et al. The human dopamine transporter gene: the 5'-flanking region reveals five diallelic polymorphic sites in a Caucasian population sample. Neurosci. Lett. 297 (2), 125-128 (2001).
51 Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain J. Neurol. 130 (7), 1819-1833 (2007).
52 Rylander D, Parent M, O'Sullivan SS et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann. Neurol. 68 (5), 619-628 (2010).
53 Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 24 (7), 1227-1251 (2007).
54 De la Fuente-Fernandez R, Nunez MA, Lopez E. The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. Clin. Neuropharmacol. 22 (4), 226-230 (1999).
55 Feldman B, Chapman J, Korczyn AD. Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease. Acta Neurol. Scand. 113 (1), 14-17 (2006).
56 Molchadski I, Korczyn AD, Cohen OS et al. The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia. Acta Neurol. Scand. 123 (2), 117-121 (2011).
57 Fujii C, Harada S, Ohkoshi N et al. Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. Clin. Genet. 56 (5), 394-399 (1999).
58 Wang J, Si Y-M, Liu Z-L, Yu L. Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease. Pharmacogenetics 13 (6), 365-369 (2003).
59 Rissling I, Korner Y, Geller F, Stiasny-Kolster K, Oertel WH, Moller JC. Preprohypocretin polymorphisms in Parkinson disease patients reporting "sleep attacks." Sleep 28 (7), 871-875 (2005).
60 Lin J-J, Yueh K-C, Lin S-Z, Harn H-J, Liu J-T. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease. J. Neurol. Sci. 252 (2), 130-134 (2007).
61 Pascale E, Purcaro C, Passarelli E et al. Genetic polymorphism of angiotensin-converting enzyme is not associated with the development of Parkinson's disease and of L-dopa-induced adverse effects. J. Neurol. Sci. 276 (1-2), 18-21 (2009).
62 Foltynie T, Cheeran B, Williams-Gray CH et al. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 80 (2), 141-144 (2009).
63 De Luca V, Annesi G, De Marco EV et al. HOMER1 promoter analysis in Parkinson's disease: association study with psychotic symptoms. Neuropsychobiology 59 (4), 239-245 (2009).
64 Schumacher-Schuh AF, Altmann V, Rieck M et al. Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients. Pharmacogenomics J. 14 (3), 289-294 (2013).
65 Ivanova SA, Loonen AJM, Pechlivanoglou P et al. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Transl. Psychiatry 2, e67 (2012).
66 Yahalom G, Kaplan N, Vituri A et al. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. Parkinsonism Relat. Disord. 18 (9), 1039-1041 (2012).
67 Goldman JG, Goetz CG, Berry-Kravis E, Leurgans S, Zhou L. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch. Neurol. 61 (8), 1280-1284 (2004).
68 Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (5123), 921-923 (1993).
69 Huang X, Chen P, Kaufer DI, Troster AI, Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch. Neurol. 63 (2), 189-193 (2006).
70 Rotzinger S, Bush DE, Vaccarino FJ. Cholecystokinin modulation of mesolimbic dopamine function: regulation of motivated behaviour. Pharmacol. Toxicol. 91 (6), 404-413 (2002).
71 Goldman JG, Marr D, Zhou L et al. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov. Disord. 26 (9), 1781-1782 (2011).
72 Labandeira-Garcia JL, Rodriguez-Pallares J, Dominguez-Meijide A, Valenzuela R, Villar-Cheda B, Rodriguez-Perez AI. Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease. Mov. Disord. 28 (10), 1337-1342 (2013).
73 Linazasoro G. New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol. Sci. 26 (8), 391-397 (2005). ** An interesting review that proposes that neural plasticity and levodopa chronic complications could be related.
74 Cenci MA, Konradi C. Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog. Brain Res. 183, 209-233 (2010).
75 Lee J-Y, Jeon BS, Kim H-J, Park S-S. Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease. Parkinsonism Relat. Disord. 18 (1), 76-78 (2012).
76 Ferrari M, Martignoni E, Blandini F et al. Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients. Eur. J. Clin. Pharmacol. 68 (11), 1493-1499 (2012).
77 Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications. Mov. Disord. 28 (1), 14-23 (2013).
78 Fahn S, Elton RL, UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Recent Developments in Parkinson's Disease. Macmillan Healthcare Information, Florham Park, NJ, USA (1987).
79 Goetz CG, Tilley BC, Shaftman SR et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23 (15), 2129-2170 (2008).
80 Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov. Disord. 23 (16), 2398-2403 (2008).
81 Fernandez HH, Aarsland D, Fenelon G et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov. Disord. 23 (4), 484-500 (2008).
|
Language: | English.
|
Document Type: | Review.
|
Journal Subset: | Life & Biomedical Sciences. Pharmacology.
|
ISSN: | 1462-2416
|
NLM Journal Code: | d0s, 100897350
|
DOI Number: | https://dx.doi.org/10.2217/pgs.1...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|